Dr Austin Kulasekararaj, consultant haematologist Kings College Hospital London, and ALXN 1210 investigator, said, “ALXN1210 could provide an effective alternative choice for treatment of both treatment-naïve PNH patients and also switching […]
Akari Therapeutics Announces Completion of Phase II COBALT Trial of Coversin in Patients with PNH and Further Progress of Clinical Trials The final three Paroxysmal Nocturnal Hemoglobinuria (PNH) patients enrolled […]
New Phase 1/2 Study Data for ALXN1210 as a Potential Future Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) to Be Presented at American Society of Hematology (ASH) Meeting Data […]
April 26, 2017 7:12 AM EDTInitial Data from Global Phase 2 Program Expected Mid-2017 CAMBRIDGE, Mass.–(BUSINESS WIRE)– Ra Pharmaceuticals, Inc. (NASDAQ: RARX) today announced that it has initiated dosing in the […]
The All Party Parliamentary Group (APPG) on Rare, Genetic and Undiagnosed Conditions published a report yesterday looking at the implementation of the UK Strategy for Rare Diseases in England. The […]
